{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 64,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "other",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a process flow diagram to illustrate dose escalation steps.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/42",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.13,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Dose escalation flow from 150x10^6 (N=6) to 450x10^6 (N=7) to 800x10^6 (N=50)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95ea2dc6-be96-4a2f-92c3-92510839f616",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.67,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "RP2D already determined at at 800x10^6. 50 patients in MM. 9 in AL.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "975b1f63-36bc-46e1-8fd6-5656fe2d4b66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: 8 patients treated in relapsed/refractory AL amyloidosis as of May 11, 2023, 5 at 800 x10^6 cells, 2 at 250 x10^6 cells, 1 at 150x10^6 cells. Multiple Myeloma data cutoff at February 9th, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2010d475-4156-49cd-9b09-db77195f126b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.02,
        "y": 0.09
      },
      "kind": "title",
      "text": "Recommended Phase 2 Dose (RP2D) Already Determined at 800x10^6",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f34092f-4a42-41ac-9e0a-46303e60919c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Ongoing Clinical Study Design (NEXICART-1/NCT04720313) in Multiple Myeloma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b29ea50-4629-40e4-8393-6d28b5ee377c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "6c1ce0c4-9a56-49dc-8af4-5e67a411f16d",
      "evidence": "title/action-title: Recommended Phase 2 Dose (RP2D) Already Determined at 800x10^6",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "f9b3331d-62c6-46e4-b892-a3db93813047",
      "evidence": "Sequential dose escalation steps",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 64,
      "from": 37,
      "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}